The cis-regulatory switchboard of pancreatic ductal cancer

Jorge Ferrer1,2 & Francisco X Real3,4

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most devastating human diseases. There is consequently a pressing need to understand its molecular underpinnings, which should enable new preventive and therapeutic strategies. A new study in The EMBO Journal (Diaferia et al., 2016) maps the transcriptome and epigenetic landscape associated with distinct PDAC grades and identifies cis- and trans-regulatory elements in tumour progression.

See also: GR Diaferia et al (March 2016)

PDAC originally acquired its name from its histological similarity with normal pancreatic ducts. However, recent work has shown that tumours with ductal morphology can arise upon activation of mutant Kras in duct-like embryonic pancreatic progenitors or in pancreatic acinar cells through a process known as acino-ductal metaplasia (Tuveson et al., 2004; Guerra et al., 2007; Pérez-Mancera et al., 2012). Acino-ductal metaplasia has thus been proposed to involve a process where acinar cells are reprogrammed to an embryonic duct cell progenitor state (Rooman & Real, 2012; Roy & Hebrok, 2015). PDAC tumours of low or moderate histological grade retain ductal features, while this phenotype is not seen in more aggressive high-grade tumours. The profound changes in cellular phenotypes that take place throughout pancreatic carcinogenesis are likely triggered by both somatic genetic alterations in tumour cells and environmental cues such as stromal-derived signals, but they need to be executed by cell-specific transcriptional programmes. This means that there should be specific transcription factors that control regulatory programmes in each histological phenotype. On the other hand, it is now known that transcription factors control cell-specific programmes through the activation of tens of thousands of transcriptional regulatory elements, including long-range enhancers and proximal promoters, which in turn activate specific cohorts of cell-specific genes. Despite recent progress in understanding the epigenome of human embryonic pancreatic progenitors (Cebola et al., 2015), so far no study has systematically tackled the transcription factor and enhancer networks that underpin ductal differentiation in normal and tumour cells.

Gioacchino Natoli and colleagues have now examined the regulatory landscape of low- and high-grade human PDAC cell lines (Diaferia et al., 2016). They generated genomewide maps of active transcripts, enhancers and promoters in these cells and found that such regulatory features showed a striking clustering with histological grade (Fig 1). They identified sets of transcription factors that are selectively expressed in low-grade PDAC, including IRF1, ELF3, FOXA1, KLF5 and HNF1B, a core marker of embryonic and adult ducts. They also defined transcription factors that were selectively expressed in high-grade PDAC, such as ZEB1, IRF1, GATA2, ETV5 and TCF12. In parallel, they interrogated genomic sequences that are selectively used as transcriptional enhancers in low-grade PDAC and found these to be highly enriched in recognition sequences for transcription factors that were found to be selectively expressed in PDAC. This finding was further corroborated by experimental analysis of genomewide binding of five of these factors. The analysis thus uncovered a core set of enhancer clusters that were specific for low-grade PDAC, several of which map to putative stage-specific regulatory genes, including KLF5. Importantly, the authors found that the transcriptional phenotype associated with stage-specific programmes could be largely explained by the activation of grade-specific enhancers.

Natoli and colleagues next tested the functional role of grade-specific transcription factors in PDAC. They used CRISPR-Cas9 to inactivate KLF5 and ELF3 in a low-grade PDAC cell line. The consequences of knocking out ELF3 were comparatively mild, but inactivation of KLF5 caused a dramatic epigenomic phenotype, with a reduction in H3K27ac and H3K4me levels (characteristic marks of active enhancers) in more than 20% of PDAC enhancers. Many of the affected enhancers were directly bound by KLF5 in wt cells, and in KLF5 knockout cells, they showed decreased binding of other transcription factors such as ELF3 and FOXA1. This suggests that KLF5 binding is required to nucleate the recruitment of transcription factors and to activate a large set of low-grade PDAC enhancers. KLF5-dependent enhancers were often located near genes that regulate proliferation and epithelial cell identity genes, and many such genes showed decreased expression in knockout

1 Section of Epigenomics and Disease, Department of Medicine, Imperial College London, London, UK. E-mail: j.ferrer@imperial.ac.uk
2 Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3 Epithelial Carcinogenesis Group, Cancer Cell Biology Programme, Spanish National Cancer Research Center-CNIO, Madrid, Spain. E-mail: freal@cnio.es
4 Departament de Ciències Experimental i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain

DOI 10.15252/embj.201693999 | Published online 18 February 2016
The control of pancreatic cancer differentiation

Jorge Ferrer & Francisco X Real

Published online: February 18, 2016

Low-grade ‘Classical’ PDAC

- KLF5
- IRF1
- ELF3
- FOXA1
- HNF1β
- ...

High-grade ‘Quasi-mesenchymal’ PDAC

- ZEB1
- GATA2
- JTV5
- IRF1
- TCF12
- ...

Figure 1. Genomewide regulatory maps identified distinct enhancers that are active in low-grade versus high-grade PDAC.

KLF5 plays a key role in the activation of low-grade PDAC enhancers, which activates epithelial transcriptional programmes, and suppresses ZEB1, a regulator of the high-grade mesenchymal PDAC transcriptional programme, which in turn suppresses the low-grade epithelial programme.

The maps of active regulatory elements in low- and high-grade PDAC are also relevant to efforts to decipher the mutational landscape of PDAC. The analysis of tumour exomes has uncovered multiple genes that are enriched in somatic mutations in PDAC, several of which are drivers of cancer initiation or progression. More recent efforts, such as Genome England’s 100,000 genomes project, aim to interrogate whole-genome sequences in human tumours. Deciphering which non-coding mutations might be relevant to PDAC pathogenesis is a formidable challenge that requires a priori knowledge of which non-coding sequences are potentially relevant to this disease. The availability of PDAC regulatory maps should provide an opportunity to test the hypothesis that mutations in specific regulatory elements contribute to PDAC through dysregulation of transcription. The pioneering work from Natoli and colleagues (Diaferia et al, 2016) therefore opens diverse avenues to further our understanding of the pathogenesis and treatment of pancreatic cancer.

Genes encoding chromatin regulatory proteins are frequently mutated in human cancers, and several of which are drivers of cancer initiation or progression (von Figura et al, 2014). The importance of transcriptional programming mechanisms in pancreatic cancer is also in keeping with recent work showing that, in mice, PDAC can be treated showing that, in mice, PDAC can be treated with small-molecule inhibitors of proteins that interact with acetylated or methylated nucleosomal histones (Mazur et al, 2015). Moreover, chromatin regulators have been shown to affect pancreatic tumour initiation or progression (von Figura et al, 2014; Richart et al, 2016). It is thus reasonable to foresee that a more detailed understanding of the transcription factor and enhancer networks that control discrete stages of PDAC will provide further opportunities to develop precision therapies.

The maps of active regulatory elements in low- and high-grade PDAC are also relevant to efforts to decipher the mutational landscape of PDAC. The analysis of tumour exomes has uncovered multiple genes that are enriched in somatic mutations in PDAC, several of which are drivers of cancer initiation or progression. More recent efforts, such as Genome England’s 100,000 genomes project, aim to interrogate whole-genome sequences in human tumours. Deciphering which non-coding mutations might be relevant to PDAC pathogenesis is a formidable challenge that requires a priori knowledge of which non-coding sequences are potentially relevant to this disease. The availability of PDAC regulatory maps should provide an opportunity to test the hypothesis that mutations in specific regulatory elements contribute to PDAC through dysregulation of transcription. The pioneering work from Natoli and colleagues (Diaferia et al, 2016) therefore opens diverse avenues to further our understanding of the pathogenesis and treatment of pancreatic cancer.

References


© 2016 The Authors

The EMBO Journal Vol 35 No 6 ¦ 2016 559
The control of pancreatic cancer differentiation

Jorge Ferrer & Francisco X Real

Published online: February 18, 2016

The EMBO Journal

Vol 35 | No 6 | 2016

© 2016 The Authors


